The Clinical Core is the key resource ofthe ADRC. Principal goals are to: (1) enroll, evaluate, characterize, and follow elderly persons, non-demented, with mild cognitive impairment, or with Alzheimer's disease or other forms of dementia, from diverse ethnic backgrounds;(2) obtain and maintain high quality data on these subjects for the Center and for the National Alzheimer's Coordinating Center (NACC);(3) provide wellcharacterized patients for clinical trials and other allied research projects;and (4) operate an autopsy program to maximize utility and amount of material for the Neuropathology Core. Goals are to increase understanding ofthe etiologies of mild cognitive impairment and dementia among individuals of differing cultural, ethnic, and socioeconomic backgrounds, improve early detection;and sharpen the accuracy of the differential diagnosis of dementia. Subjects are recruited from the Columbia University memory centers operating at The Neurological Institute, New York State Psychiatric Institute, Harlem Hospital Satellite, and from volunteers and community-dwelling persons receiving healthcare from a nearby collaborating facility, Isabella Geriatric Center. The Clinical Core recruits a sample including about 20% Hispanics, 11% African-Americans, and 2.5% Asians. The Core performs rigorous standardized medical, neurologic, psychiatric, neuropsychological, neuroimaging, and biological sample evaluation. The Core interacts closely with the Genetics Core in genotyping, storage, and disbursement of samples. The Core works integrally with the Data Core to ensure standardized, high quality, complete data collection including the Uniform Data Set (UDS). Interface with Education Core improves visibility and understanding of diseases, clinical trials, and autopsy program. Coordination with Neuropathology Core results in maximizing utility of brain tissue for genetic, mitochondrial, epigenetic, biochemical, proteomic, and gene expression investigations. Subjects enroll in affiliated federal, foundation, and pharmaceutical company funded research studies. These include clinical drug trial, genetic epidemiology, neuroimaging and neuropsychological studies, and research into risk factors, predictors, and contributing conditions in cognitive change during aging and dementia.

Public Health Relevance

Alzheimer's disease is a major public health problem with huge social, societal, and monetary costs. The Clinical Core provides human subject resources that permit furthering of research at Columbia University Medical Center, nationally, and internationally, directed towards ultimately reducing the burden of this disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG008702-24
Application #
8574144
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
24
Fiscal Year
2013
Total Cost
$611,207
Indirect Cost
$229,254
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Winawer, Melodie R; Griffin, Nicole G; Samanamud, Jorge et al. (2018) Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. Ann Neurol 83:1133-1146
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416

Showing the most recent 10 out of 640 publications